DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: OCREVUS (ocrelizumab)
*****************************************************
#Post#: 2186--------------------------------------------------
Ocrevus the "most impressive drug launch of 2017" (Bio
PharmaDive)
By: agate Date: August 17, 2018, 9:53 am
---------------------------------------------------------
Back in December 2017, BioPharmaDive regarded Ocrevus as the
most impressive drug launch of 2017--"Most Impressive Drug
Launch: Roche's Ocrevus."
HTML https://www.biopharmadive.com/news/most-impressive-drug-launch-roche-ocrevus-2017/510814/
#Post#: 2253--------------------------------------------------
Ocrevus called a blockbuster drug
By: agate Date: October 18, 2018, 7:58 pm
---------------------------------------------------------
Ocrevus is turning out to be a blockbuster drug, according to
PMLive, a pharmaceutical news Website (October 17, 2018):
[quote]
[font=inherit]Sales of Roche’s new multiple sclerosis therapy
Ocrevus more than tripled in the first nine months of 2018,
helping to compensate for the loss of patent protection on its
older blockbuster drugs.[/font]
[font=inherit]Ocrevus
HTML http://www.pmlive.com/pharma_news/roches_ocrevus_is_first_primary_progressive_ms_drug_in_eu_1216820[/font][/size]<br
/>(ocrelizumab) only made its debut in the US last year, but has
already vaulted itself to blockbuster status, with sales up 238%
to CHF 1.67bn ($1.68bn). Roche said it has seen strong uptake in
both relapsing-remitting and primary progressive forms of MS in
the US, which still accounts for more than 90% of the drug’s
sales, with Europe gaining traction with sales of CHF 130m.
[/quote][font=inherit]CHF = Swiss francs[/font][size=15px]
*****************************************************